Carlsmed Reports 65% Revenue Growth and Raises Full Year 2026 Guidance
Carlsmed (CARL) reported strong third-quarter results for fiscal year 2026, highlighted by a 65% year-over-year revenue increase to $21.6 million. This growth was primarily driven by the rapid adoption of the aprevo lumbar platform and increasing contributions from its cervical platform. Consequently, management raised its full-year 2026 revenue guidance to a range of $78 million to $80 million. The company is demonstrating signs of improving operational efficiency, with gross margins expanding to 77.3% due to lower manufacturing costs and production efficiencies. While the company reported an adjusted net loss per share of $0.34, this represents an improvement over the prior year's $0.40 loss, signaling positive operating leverage as procedure volumes grew by 76%.
Topics: Gross Margin Expansion Guidance Raise Medical Devices Revenue Growth